---
title: "Ocugen’s (OCGN) Stock Surges 195% on Promising Gene Therapy Treatment"
description: "Ocugen's stock has surged 195% over the past year, driven by its innovative gene therapy platform targeting retinal diseases. The company is advancing several treatment candidates, including OCU400 fo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/214037527.md"
published_at: "2024-09-11T07:14:24.000Z"
---

# Ocugen’s (OCGN) Stock Surges 195% on Promising Gene Therapy Treatment

> Ocugen's stock has surged 195% over the past year, driven by its innovative gene therapy platform targeting retinal diseases. The company is advancing several treatment candidates, including OCU400 for retinitis pigmentosa, currently in Phase 3 trials, and has received FDA approval for an expanded access program. Despite a recent revenue of $0.14 million and a 30% decline in operating expenses, analysts maintain a positive outlook, with a price target of $2.00, indicating a potential upside of 504.84%. Ocugen is positioned as a strong investment opportunity in the biotech sector.

Ocugen (OCGN) is grabbing investors’ attention with its stock climbing 195% in the past year and its modifier gene therapy platform, which promises to deliver one-time treatments that could change the approach to many retinal diseases. The company is positioned as a front-runner in a pursuit that could potentially impact millions suffering from retinal diseases like retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). Ocugen’s pioneering gene therapies also offer hope for those affected by geographic atrophy (GA) and dry age-related macular degeneration (dAMD).

The company is poised to tap into vast market opportunities with an extensive potential U.S. and European patient base. The stock has the potential to see further significant growth, making OCGN a compelling opportunity in the biotech industry.

## **Ocugen’s Promising Treatment Candidates**

Ocugen is a biotechnology firm focused on making strides in the global health sector with gene and cell therapies and vaccines. The company has crafted a cutting-edge modifier gene therapy platform that shows potential in treating a range of retinal diseases with a single treatment.

In the first half of 2024, the company achieved critical milestones in advancing several promising treatment candidates. OCU400, a retinitis pigmentosa (RP) treatment, is currently in a Phase 3 clinical trial. At the same time, the FDA recently approved an expanded access program (EAP) for adults with RP, marking the first-ever EAP approval for a gene therapy candidate to treat patients with RP, irrespective of mutation.

Additionally, Ocugen is actively developing OCU410 (in Phase 2 clinical trial) and OCU410ST, gene therapies aimed at treating geographic atrophy secondary to dry age-related macular degeneration (dAMD) and Stargardt disease. OCU410ST has already received an Orphan Drug Designation from the FDA.

## **Analysis of Ocugen’s Recent Financial Results**

The company recently reported results for Q2 2024, posting revenue of $1.14 million. Total operating expenses declined roughly 30% from $24 million in Q2 2023 to $16.6 million. This decline was attributed to lower research and development and general and administrative expenses. GAAP earnings per share (EPS) of -$0.04 marked a 60% year-over-year decrease in net loss per common share while beating analyst expectations by $0.01.

The company issued a new offering of common stock during the quarter and received a net cash influx of $32.6 million. However, the company’s total cash and cash equivalents dipped from $39.5 million as of December 31, 2023, to $16 million as of June 30, 2024.

## **What Is the Price Target for OCGN Stock?**

The stock has been trending upward, climbing roughly 114% year-to-date. It trades near the middle of its 52-week price range of $0.35 – $2.11 and shows negative price momentum by trading below its 20-day (1.27) and 50-day (1.38) moving averages.

Analysts covering the company have been constructive on OCGN stock. For example, H.C. Wainwright analyst Swayampakula Ramakanth recently reiterated a Buy rating on the shares while keeping the price target at $7.00, noting the company’s promising clinical advancements and significant cash reserve that is projected to fund operations into the third quarter of 2025.

Ocugen is rated a Moderate Buy based on two analysts’ recent recommendations and price targets. The average price target for OCGN stock is $7.50, representing a potential upside of 504.84% from current levels.

**See more OCGN analyst ratings**

## **OCGN in Summary**

Ocugen’s treatment candidates hold transformative potential for a range of retinal diseases. Its innovative pipeline is seeing progress with several candidates in clinical trials, with one receiving recent FDA approval for an expanded access program for RP treatment, marking a first-of-its-kind move for gene therapy. With the stock surging over the past year and an average price target suggesting a significant upside, OCGN is an attractive opportunity for investors looking for a high-potential contender in biotechnology.

Disclosure

### Related Stocks

- [OCGN.US - Ocugen](https://longbridge.com/en/quote/OCGN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Ocugen 表示基因疗法在眼病试验中将病变的增长减少了 46% | Ocugen (OCGN) 宣布其基因疗法 OCU410 的积极初步二期结果，该疗法在因干性年龄相关性黄斑变性导致的地理性萎缩患者中减少了 46% 的病变生长。中剂量组的减少幅度为 54%，而高剂量组的减少幅度为 36%。未报告严重不良事件 | [Link](https://longbridge.com/en/news/272716046.md) |
| Ocugen 宣布将进行第二阶段 OCU410 临床试验数据的网络直播 | Ocugen Inc. 将于 2026 年 1 月 15 日上午 8:30（东部时间）召开电话会议和直播网络研讨会，讨论 OCU410 第二阶段 ArMaDa 临床试验的数据。此次活动将邀请研究调查员和 Ocugen 的高管团队，展示试验结 | [Link](https://longbridge.com/en/news/272407535.md) |
| Ocugen 的早期基因疗法数据显示视力损害减少了 46% | Ocugen, Inc. 报告了其基因治疗 OCU410 的早期二期数据，显示在患有地理性萎缩的患者中，病灶生长减少了 46%，且没有严重的安全问题。尽管这一积极数据，Ocugen 的股票仍下跌了 9.08%，至 1.71 美元，与主要市场 | [Link](https://longbridge.com/en/news/272737139.md) |
| Ocugen 股价上涨，因其基因疗法在治疗致盲眼病方面显示出希望 | 制药公司 Ocugen 的股票在盘前上涨 2.7%，至 1.93 美元。该公司表示，其实验性疗法 OCU410 减缓了地理性萎缩的进展，这是一种严重的年龄相关性黄斑变性。接受治疗的患者中约有一半的眼部病变增长减少了 46%，而中等剂量的治疗 | [Link](https://longbridge.com/en/news/272704395.md) |
| Ocugen, Inc. 完成了 2250 万美元的股票发行 | 2026 年 1 月 23 日，Ocugen, Inc. 宣布完成 2250 万美元的股票发行。主要亮点：Ocugen 完成了 1500 万股的发行，每股价格为 1.50 美元。预计净收益为 2085 万美元，将用于延长现金流。资金将用于公 | [Link](https://longbridge.com/en/news/273520024.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
